Participants
Contact
The University of Barcelona has produced a video about research on the synthesis of antitumor compounds of marine origin performed by Fernando Albericio’s group at IRB. The video focuses on a study carried out in collaboration with the company PharmaMar that has resulted in a compound, pipecolidepsin A, which is effective against eleven types of cancers.
IRB and PharmaMar invent a method to reproduce marine substances of pharmacological interest
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
